- • Up to 20% off your first purchase
- • Bulk quantities available
- • Citation Reward application
Sample Application
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library
|
|
Recombinant multi-species Cardiac Troponin I/TNNI3 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis
Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine Cardiac Troponin I/TNNI3 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
Troponin I (TnI), along with troponin T (TnT) and troponin C (TnC), is one of 3 subunits that form the troponin complex of the thin filaments of striated muscle. TnI is the inhibitory subunit; blocking actin-myosin interactions and thereby mediating striated muscle relaxation. The TnI subfamily contains three genes: TnI-skeletal-fast-twitch, TnI-skeletal-slow-twitch, and TnI-cardiac. This gene encodes the TnI-cardiac protein and is exclusively expressed in cardiac muscle tissues. Mutations in this gene cause familial hypertrophic cardiomyopathy type 7 (CMH7) and familial restrictive cardiomyopathy (RCM). Troponin I is useful in making a diagnosis of heart failure, and of ischemic heart disease. An elevated level of troponin is also now used as indicator of acute myocardial injury in patients hospitalized with moderate/severe Coronavirus Disease 2019 (COVID-19). Such elevation has also been associated with higher risk of mortality in cardiovascular disease patients hospitalized due to COVID-19. [provided by RefSeq, Aug 2020]
The Alternative Names of target: CMD1FF,CMD2A,CMH7,Cardiac Troponin I,Cardiac troponin I,RCM1,TNNC1,TNNI3,Tn1,TnI,Tnni3,Troponin I,cTNI,cTnI,cardiac muscle
Go
to Cardiac Troponin I/TNNI3 products collection
>>
(antibodies,
antigen, VLP, mRNA, ORF viral vector, etc)
MSDSProduct information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-T20186-Ag-1/ GM-Tg-hg-T20186-Ag-2 | Human Cardiac Troponin I/TNNI3 protein | Human |
| GM-Tg-rg-T20186-Ag-1/ GM-Tg-rg-T20186-Ag-2 | Rat Cardiac Troponin I/TNNI3 protein | Rat |
| GM-Tg-mg-T20186-Ag-1/ GM-Tg-mg-T20186-Ag-2 | Mouse Cardiac Troponin I/TNNI3 protein | Mouse |
| GM-Tg-cynog-T20186-Ag-1/ GM-Tg-cynog-T20186-Ag-2 | Cynomolgus/Rhesus macaque Cardiac Troponin I/TNNI3 protein | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-T20186-Ag-1/ GM-Tg-felg-T20186-Ag-2 | Feline Cardiac Troponin I/TNNI3 protein | Feline |
| GM-Tg-cang-T20186-Ag-1/ GM-Tg-cang-T20186-Ag-2 | Canine Cardiac Troponin I/TNNI3 protein | Canine |
| GM-Tg-bovg-T20186-Ag-1/ GM-Tg-bovg-T20186-Ag-2 | Bovine Cardiac Troponin I/TNNI3 protein | Bovine |
| GM-Tg-equg-T20186-Ag-1/ GM-Tg-equg-T20186-Ag-2 | Equine Cardiac Troponin I/TNNI3 protein | Equine |
Size： 1mg | 10mg | 100mg
Product Description
| Catalog No. |
GM-Tg-hg-T20186-Ag-1/ GM-Tg-hg-T20186-Ag-2;
GM-Tg-rg-T20186-Ag-1/ GM-Tg-rg-T20186-Ag-2;
GM-Tg-mg-T20186-Ag-1/ GM-Tg-mg-T20186-Ag-2; GM-Tg-cynog-T20186-Ag-1/ GM-Tg-cynog-T20186-Ag-2; GM-Tg-felg-T20186-Ag-1/ GM-Tg-felg-T20186-Ag-2; GM-Tg-cang-T20186-Ag-1/ GM-Tg-cang-T20186-Ag-2; GM-Tg-bovg-T20186-Ag-1/ GM-Tg-bovg-T20186-Ag-2; GM-Tg-equg-T20186-Ag-1/ GM-Tg-equg-T20186-Ag-2 |
| Products Name | Cardiac Troponin I/TNNI3 protein |
| Species | Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine |
| Target Name | Cardiac Troponin I/TNNI3 |
| Protein Sub-location | Introcelluar Protein |
| Isotypes | Recombinant protein |
| Expression platform | Mammalian cell |
| Bioactivity validation | Affintiy&bioactivity validated by ELISA, cell culture validated. |
| Tag | His |
| Products description | Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine Cardiac Troponin I/TNNI3 protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution |
Lyophilized from GM's Protein Stability Buffer2
(PSB2,Confidential Ingredients) or PBS
(pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
About Gmab
GMab, developed by GeneMedi, constitutes an
advanced library of recombinant
monoclonal antibodies, each meticulously
designed to target specific molecular
entities. Leveraging the sophisticated
capabilities of GM’s Taurus™ and LIBRA™
platforms, GMab synthesizes antibodies
characterized by high binding affinity,
exceptional physicochemical stability, and
optimal developability profiles.
Through
expression in mammalian cell lines, GMab has
been established as a paradigmatic
reference antibody. It holds significance in
myriad domains of biological drug
discovery, encompassing cellular cultivation,
innovative assay methodologies,
strategic animal model systematization, in-depth
pharmacokinetic & pharmacodynamic
(PK/PD) modeling, and intricate mechanism of
action (MOA) investigations.